Key result
Impaired flow-mediated dilation (≤5.36%) was independently associated with a significantly increased risk of all-cause mortality (HR 9.80) in kidney transplant recipients.
Why the study?
Endothelial dysfunction is an early, potentially reversible stage in atherosclerosis, but its association with mortality and graft outcomes in kidney transplant recipients required evaluation.
Does impaired flow-mediated dilation predict mortality and graft loss in kidney transplant recipients?
Cohort (n=145)
No
Does impaired flow-mediated dilation predict mortality and graft loss in kidney transplant recipients?
Impaired endothelial function, measured noninvasively by flow-mediated dilation, is strongly and independently associated with long-term mortality and graft loss in kidney transplant recipients.
Should not yet alter post-transplant management; leaves open whether endothelial dysfunction is a modifiable prognostic target.
Background. Endothelial dysfunction is an early and potentially reversible stage in the atherosclerotic process. We assessed endothelial dysfunction noninvasively in kidney transplant recipients (KTRs) and evaluated the association with mortality and graft outcomes. Methods. Flow-mediated dilation (FMD) was measured in arteria brachialis by ultrasound, with baseline diameters obtained at rest and maximal diameters obtained during reactive hyperemia occurring after 5 min of forearm occlusion. FMD% is the percentage difference of flow-mediated dilation relative to baseline. Endpoints on mortality and graft outcomes were collected from The Norwegian Renal Registry. The distribution of risk according to FMD levels was assessed in Cox regression using a restricted cubic spline function. FMD was dichotomized using receiver operating characteristic analysis to identify optimal cut points at maximal sensitivity and specificity. Results. From a total of 269 KTRs in 2012, 152 (56.5%) were eligible and examined 10 wk after transplantation, and 145 had successful FMD measurements. During a mean follow-up of 6.5 y, 26 patients died, 11 lost their graft, and 34 experienced either graft loss or death. Mortality increased with lower FMD levels until about 5% dilation and did not change with further reduction in FMD% ( P for nonlinearity <0.01). An optimal cut point of FMD ≤5.36% defined impaired endothelial function and FMD% below this level, was associated with fatal outcome, hazard ratio (HR), 9.80 (1.29–74.62), P = 0.03, uncensored graft loss, HR, 7.80 (1.83–33.30), P = 0.01, but an association with death-censored graft loss was lost after adjusting for pulse pressure, HR, 4.58 (0.55–37.92), P = 0.16. Conclusions. We found that impaired FMD is strongly associated with mortality in KTRs.
No takes yet. Share an insight, caveat, or question.
Langberg et al. (2021) conducted a cohort in Kidney transplant recipients (n=145). Impaired flow-mediated dilation (≤5.36%) vs. Normal flow-mediated dilation (>5.36%) was evaluated on All-cause mortality (HR 9.80, 95% CI 1.29-74.62, p=0.03). Impaired flow-mediated dilation (≤5.36%) was independently associated with a significantly increased risk of all-cause mortality (HR 9.80) in kidney transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: